Finishing cancer treatment should feel like crossing a finish line. For many lung cancer patients, though, the wait that follows is the hardest part.
Every follow-up scan feels like a quiet verdict on whether the disease has come back.
A new study from NYU Langone Health in New York suggests that answer may arrive much sooner. Researchers found a blood test that could flag a lung cancer recurrence a median of 16.7 months before standard imaging scans picked up anything.
The findings were published in November 2026 in The Journal of Molecular Diagnostics. The test looks for tiny traces of tumor DNA in a routine blood sample.
Also read: New study reveals why sugar could be more dangerous for some men
That lead time matters because lung cancer is the deadliest cancer in the world. The World Health Organization estimates about 1.8 million lung cancer deaths each year, more than any other type.
How the blood test picks up cancer DNA
Tumors do not stay silent, even when they are too small to see. Cancer cells break down and release fragments of their DNA into the bloodstream. These fragments are called circulating tumor DNA, or ctDNA for short.
The NYU team built a personal signature of each patient's tumor DNA. They then looked for that signature in routine blood samples drawn after surgery.
A pattern-recognition tool trained with artificial intelligence sifted through the data to pick out the few cancer fragments among the normal DNA.
Also read: Scientists discover a village where women are three times more likely to reach 100
If matching DNA appeared in later blood draws, it was a sign that microscopic cancer cells had survived treatment and started to multiply again.
What the study found in early-stage lung cancer
The researchers tracked 42 people treated for stage IA non-small cell lung cancer. This is the most common form of the disease and the kind caught at its earliest point. Even at that stage, recurrence is a known risk after surgery.
In the group, the test correctly flagged roughly three out of four patients who went on to relapse. Nearly all patients with a clean ctDNA result stayed in remission. On average, the blood test raised the alarm 16.7 months before scans or symptoms did.
Lead investigator Matija Snuderl, a pathologist at NYU Langone Health, spoke to Inside Precision Medicine about the approach.
Also read: AI detects deadly cancer 475 days before doctors diagnose it
He said these blood tests are becoming an important way to monitor patients between the end of treatment and any later sign of recurrence.
What this means for patients today
Here is the honest part. The test is not available in your doctor's office. It is still a research tool, built around a small group of 42 patients.
The authors stressed the findings must be confirmed in larger studies before anyone changes how lung cancer survivors are followed. A positive signal in the blood also does not guarantee that a tumor will grow back in a way doctors can treat differently.
A negative result does not completely rule out leftover disease either.
Also read: You don't have to lose weight to improve your heart health, research suggests
Earlier detection is only useful if it leads to earlier treatment that actually extends life, and that question is still open.
Anyone treated for lung cancer should keep going to scheduled follow-ups with their oncologist, which remain the standard way to catch a return of the disease.
Also read: These 8 symptoms could mean your thyroid is overactive
This article is made and published by Ida-Marie Palm Varbæk, who may have used AI in the preparation.